Why Now: Pharma profits 💊 are deterring as unit cost of goods are rising

Pharma being a heavily regulated industry, it means cost of goods are generally high. However, with the recent inflation it has started to become a key challenge across key players such as Pfizer, BMS, Novartis, and more. Resulting in frequent layoffs, restructuring of portfolio's and sale of entire business units.

However, with the recent advancements of Large language models (LLMs) and Artificial Intelligence (AI) it provides an opportunity to bring a new era of process efficiencies in regulated activities such as validation. Simplifying work procedures by eliminating repetitive tasks and increasing overall organisational productivity.

At ValidateX, with this core-principle in mind our aim is to enable unit-cost reduction across the manufacturing processes in all regulated environments. Starting with a focus on Validation activities.